Incident long-term warfarin use and risk of osteoporotic fractures: Propensity-score matched cohort of elders with new onset atrial fibrillation

Osteoporosis International

Volumn 25, Issue 6, 2014, Pages 1677-1684

  Misra, D ^a   Zhang, Y ^a,b   Peloquin, C ^a   Choi, H K ^a   Kiel, D P ^c   Neogi, T ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Fracture; Oral anti coagulant; Osteoporosis; Warfarin

Indexed keywords

RALOXIFENE; STRONTIUM RANELATE; WARFARIN; ANTICOAGULANT AGENT;

AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; FRAGILITY FRACTURE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK; SPINE FRACTURE; WRIST FRACTURE; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG UTILIZATION; EPIDEMIOLOGY; FACTUAL DATABASE; HIP FRACTURES; INCIDENCE; MULTICENTER STUDY; OSTEOPOROTIC FRACTURES; PROCEDURES; RISK ASSESSMENT; SPINAL FRACTURES; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VERY ELDERLY; WRIST INJURIES;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; GREAT BRITAIN; HIP FRACTURES; HUMANS; INCIDENCE; MALE; OSTEOPOROTIC FRACTURES; PROPENSITY SCORE; RISK ASSESSMENT; SPINAL FRACTURES; WARFARIN; WRIST INJURIES;

EID: 84901826950     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2662-0     Document Type: Article

References (34)

1. Rubinacci A (2009) Expanding the functional spectrum of vitamin K in bone. Focus on: "Vitamin K promotes mineralization, osteoblast to osteocyte transition, and an anti-catabolic phenotype by {gamma}-carboxylation-dependent and-independent mechanisms". Am J Physiol Cell Physiol 297:C1336-C1338
2. Price PA (1989) Gla-containing proteins of bone. Connect Tissue Res 21:51-57, discussion 7-60
3. Price PA (1985) Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 42:65-108
4. Furie B, Bouchard BA, Furie BC (1999) Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 93:1798-1808
5. Booth SL, Broe KE, Gagnon DR et al (2003) Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr 77:512-516
6. Kanai T, Takagi T, Masuhiro K, Nakamura M, Iwata M, Saji F (1997) Serum vitamin K level and bone mineral density in post-menopausal women. Int J Gynaecol Obstet 56:25-30
7. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA (1999) Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 69:74-79
8. Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD (1993) Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 8:1241-1245
9. Gundberg CM, Lian JB, Booth SL (2012) Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr 3:149-157
10. Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 18:487-488
11. Luukinen H, Herala M, Koski K, Honkanen R, Laippala P, Kivela SL (2000) Fracture risk associated with a fall according to type of fall among the elderly. Osteoporos Int 11:631-634
12. Knapen MH, Hamulyak K, Vermeer C (1989) The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 111:1001-1005
13. Haffa A, Krueger D, Bruner J et al (2000) Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res 15:872-878
14. Whitlon DS, Sadowski JA, Suttie JW (1978) Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17:1371-1377
15. Jamal SA, Browner WS, Bauer DC, Cummings SR (1998) Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 128:829-832
16. Caraballo PJ, Heit JA, Atkinson EJ et al (1999) Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159:1750-1756
17. Mamdani M, Upshur RE, Anderson G, Bartle BR, Laupacis A (2003) Warfarin therapy and risk of hip fracture among elderly patients. Pharmacotherapy 23:1-4
18. Pilon D, Castilloux AM, Dorais M, LeLorier J (2004) Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf 13:289-294
19. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166:241-246
20. Woo C, Chang LL, Ewing SK, Bauer DC (2008) Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J Am Geriatr Soc 56:1171-1176
21. Eastell R (2006) Nat Clin Pract Endocrinol Metab 2:484-485
22. Sato Y, Honda Y, Jun I (2010) Long-term oral anticoagulation therapy and the risk of hip fracture in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Cerebrovasc Dis 29:73-78
23. Rejnmark L, Vestergaard P, Mosekilde L (2007) Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 118:338-344
24. Danaei G, Tavakkoli M, Hernan MA (2012) Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175:250-262
25. AGS Clinical Practices Committee. American Geriatric Society (2000) The use of oral anticoagulants (warfarin) in older people. J Am Geriatr Soc 48:224-227
26. Bourke A, Dattani H, Robinson M (2004) Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 12:171-177
27. D'Agostino R Jr (1998) Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281
28. Seeger JD, Williams PL, Walker AM (2005) An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 14:465-476
29. Soriano L (2011) A UK primary care study on acid-suppressive drugs and hip fracture: is there a link? Gut 60:A36
30. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953
31. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76-83
32. Targownik L, Lix L, Metge C, Prior H, Leung S, Leslie W (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319-326
33. Brown DL, Morgenstern LB, Majersik JJ, Kleerekoper M, Lisabeth LD (2008) Risk of fractures after stroke. Cerebrovasc Dis 25:95-99
34. Kanis J, Oden A, Johnell O (2001) Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke 32:702-706